HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality
Investigating morbidity and mortality in an HIV/HCV‐coinfected population in care
View PublicationInvestigating morbidity and mortality in an HIV/HCV‐coinfected population in care
View PublicationEvaluating factors associated with insulin resistance in a cohort of HIV/HCV-coinfected patients
View PublicationDescribing the characteristics of coinfected patients who could be eligible for direct-acting antivirals
View PublicationExamining the impact of ART interruption on liver fibrosis progression in co-infected adults
View PublicationInvestigating whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection
View PublicationAssessing risk factors for reinfection after sustained virologic response in a representative cohort of Canadian coinfected patients in clinical care
View PublicationInvestigating the role of programmed death‐1and T‐cell immunoglobulin and mucin domain‐containing molecule‐3 expression in T‐cell exhaustion during HCV/HIV co‐infection
View PublicationInvestigating the relationship between cumulative HAART exposure and hepatic fibrosis
View PublicationEvaluating the evolution of a noninvasive measure of liver fibrosis and determining its predictive value for hepatic outcomes in HIV-positive patients with and without HCV coinfection
View Publication